HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Patent & Trademark Office reform legislation

This article was originally published in The Rose Sheet

Executive Summary

Patent & Trademark Office reform legislation: Senate Judiciary Committee Orrin Hatch's (R-Utah) S 507 is focus of May 7 Senate hearing at 10:00 in Dirksen room 226. The bill would establish the U.S. Patent and Trademark Organization as a government corporation. On the House side, Rep. Howard Coble's (R-N.C.) HR 400 passed the floor by a voice vote April 23. The legislation embraced the floor manager's amendment offering a compromise of a proposal submitted by the Administration, which leaves intellectual property policy development to the Commerce department under a new under secretary. Management and operational functions will be vested completely in the PTO led by a director within the office who will be responsible for granting patents and issuing trademarks...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel